Lifecore Biomedical, Inc. LFCR Fair Value Measurement Disclosure
Fair Value Measurement Disclosure at other companies
Other financials
Where this comes from
Reported directly by Lifecore Biomedical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue.
The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lifecore Biomedical, Inc.'s fair value measurement disclosure.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lifecore Biomedical, Inc.'s fair value measurement disclosure?
- Lifecore Biomedical, Inc. (LFCR) reported fair value measurement disclosure of $29.72M in Q1 2026.
- What is the long-term trend for Lifecore Biomedical, Inc.'s fair value measurement disclosure?
- Over 3 years (2021 to 2026), Lifecore Biomedical, Inc.'s fair value measurement disclosure has grown at a -13.0% compound annual growth rate (CAGR), from $45.1M to $29.72M.
- What does fair value measurement disclosure mean?
- This represents the aggregate carrying amount of assets and liabilities that are measured at fair value on a recurring or non-recurring basis. It provides transparency into the valuation techniques and inputs used to determine these values, categorized by the fair value hierarchy. This is critical for asset managers holding diverse investment portfolios.